Cells · 2023 · 13 citations · 27 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyDrug DiscoveryMolecular PharmacologyCardiac PharmacotherapyCardiovascular PharmacologyHeart FailureHeart Failure PharmacotherapyCardioprotective TherapyHeart Failure Molecular MechanismsHeart Failure PharmacologyHeart Failure PhysiologyLeft Ventricular Ejection Fraction DeclineNovel Cardiovascular Drug DevelopmentTricarboxylic Acid Cycle FluxTricarboxylic Acid Cycle Intermediates
Heart failure with reduced ejection fraction (HFrEF) is characterized not only by reduced left ventricular ejection fraction (EF) but is also combined with symptoms such as dyspnea, fatigue, and edema. Several pharmacological interventions have been established. However, a treatment targeting a novel pathophysiological mechanism is still needed. Evidence indicating that inhibition of pyruvate dehydrogenase kinase 4 (PDK4) may be cardioprotective has been accumulating. Thus, we focused on vitamin K3 and used its framework as a new PDK4 inhibitor skeleton to synthesize new PDK4 inhibitors that show higher activity than the existing PDK4 inhibitor, dichloroacetic acid, and tested their cardioprotective effects on a mouse heart failure model. Among these inhibitors, PDK4 inhibitor 8 improved EF the most, even though it did not reverse cardiac fibrosis or wall thickness. This novel, potent PDK4 inhibitor may improve EF of failing hearts by regulating bioenergetics via activation of the tricarboxylic acid cycle.
27
Fiji: an open-source platform for biological-image analysis
Johannes Schindelin, Ignacio Arganda‐Carreras, Erwin Frise et al. · Nature Methods · 2012 · 70.9K citations
2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary
Clyde W. Yancy, Mariell Jessup, Biykem Bozkurt et al. · Circulation · 2013 · 3.3K citations
Marlies Antlanger, Stefan Aschauer, Chantal Kopecky et al. · Kidney & Blood Pressure Research · 2017 · 2.8K citations · Full text